BACTIGUARD Aktie

 

At Bactiguard Holding AB's (publ) Annual General Meeting (AGM) on 15 May 2025, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2024 and decided that no dividend for the financial year 2024 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board of Directors and CEOs were discharged from liability for their administration of the company for the financial year 2024. The AGM resolved that the remuneration until the next AGM shall be paid in an amount of SEK 750,000 to the Chairman of the...

Continued profitability and revenue growth for Bactiguard First quarter 2025 (January – March) · Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%. · Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million corresponding to 9.5%. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3%. · Operating loss amounted to SEK 2.6 (12.9) million. · EBITDA amounted to SEK 9.4 (-1.5) million. · Net loss for the period amounted to SEK 4.7 (9.9) million. · Loss per share, before and after...

The Annual and Sustainably Report 2024 for Bactiguard Holding AB (publ) is now available at ir.bactiguard.com/ In 2024, Bactiguard completed the strategic shift needed to enable the company to be the premier choice for both current and future partners. This transformation delivered positive financial results and positioned Bactiguard for growth. The company achieved EBITDA profitability, which was a core commitment to its shareholders, along with positive cash flow from operating activities. Reaching these milestones marks a significant achievement, allowing Bactiguard to further develop its...

Bactiguard Holding AB (publ) publishes its interim report for the first quarter on Thursday 24 April 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com (https://ir.bactiguard.com/report/q1-2025/). To participate in the audiocast, please use this link: ir.bactiguard.com/report/q1-2025/ To participate only by conference call, please register via the...

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Thursday, 15 May 2025 at 9 am at Posthuset 7A, Vasagatan 28 in Stockholm. Registration will commence at 8 am. Right to participate and notice of intent to participate Shareholders wishing to participate in the Annual General Meeting must: · be recorded in the share register maintained by Euroclear Sweden AB (“Euroclear”) on Wednesday 7 May 2025 (“the record date”) · provide notice to the company of their...

The Nomination Committee of Bactiguard Holding AB (the "Company") today informs about the proposal regarding the composition of the Board of Directors for the Annual General Meeting on 15 May 2025. The Nomination Committee proposes re-election of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg as Board Members. Thomas von Koch is proposed to be re-elected as the Chairman of the Board of Directors. The Nomination Committee's other proposals will be made public in the notice convening the Annual General Meeting to be held on 15 May 2025....

Bactiguard Holding AB (publ.) today announces its updated strategic and financial targets following a review announced in connection with the 2024 Q3 report. The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation delivered in 2024. The updated strategic and financial targets will be presented at an audiocast tomorrow 6 March at 10:00 CET. Bactiguard has conducted a comprehensive analysis of the market potential and partnership opportunities for its infection prevention technology. This includes an in-depth evaluation of key...

Bactiguard Holding AB (publ) publishes its year-end report for 2024 on Thursday 6 February 2025 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com. To participate in the audiocast, please use this link: ir.bactiguard.com/report/q4-2024/ To participate only by conference call, please register via the link above. Questions can be asked either in writing via...

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Thursday 15 May 2025 in Stockholm, has been appointed. The Nomination Committee will consist of: · Helena Borglund (appointed by TomBact AB) · Christian Kinch (appointed by GIDL Invest AB) · Jan Ståhlberg (appointed by Jan Ståhlberg) · Mats J Andersson (appointed by Nordea Fonder) · Jannis Kitsakis (appointed by Fjärde AP Fonden) In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of...

Bactiguard delivers positive EBITDA and initiates review of 2028 financial targets due to previously announced agreement termination Third quarter 2024 (July – September) · Total revenue amounted to SEK 73.9 (49.5) million, an increase of SEK 24.5 million corresponding to 49.4%. · Net sales amounted to SEK 67.3 (45.5) million, an increase of SEK 21.9 million corresponding to 48.1%. Adjusted for currency effects of SEK -4.2 million, net sales increased by 57.5%. · Operating loss amounted to SEK 1.9 (21.6) million. · EBITDA amounted to SEK 9.9 (-9.5) million. · Net loss for...

Bactiguard Holding AB (publ) publishes its interim report for the third quarter on Thursday 24 October 2024 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com (https://ir.bactiguard.com/report/q3-2024/). To participate in the audiocast, please use this link: ir.bactiguard.com/report/q3-2024/ To participate only by conference call, please register via the...

Zimmer Biomet has informed Bactiguard that they terminate the license agreement signed in 2022 covering multiple orthopedic product segments. The reason stated is the more complex and lengthier path with the US Food and Drug Administration (FDA) than initially expected by Zimmer Biomet. There will be no negative financial impact for Bactiguard for 2024 related to this termination. Bactiguard is in dialogue with the team at Zimmer Biomet to evaluate further details and the impact of the termination and will revert with more information once available. The partnership with Zimmer Biomet...

License revenues and EBITDA stabilizing Second quarter 2024 (April – June) · Total revenue amounted to SEK 60.9 (51.2) million, an increase of SEK 9.7 million corresponding to 18.9%. · Net sales amounted to SEK 57.4 (44.2) million, an increase of SEK 13.2 million corresponding to 29.8%. Adjusted for currency effects of SEK 0.2 million, net sales increased by 30.1%. · Operating loss amounted to SEK 10.8 (67.8) million.* · EBITDA amounted to SEK 1.2 (-55.7) million.* · Net loss for the period amounted to SEK 14.3 (64.5) million.* · Loss per share, before and after dilution,...

Bactiguard Holding AB (publ) publishes its interim report for the second quarter on Tuesday 16 July 2024 at 07:00 CET. In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at Bactiguard's website bactiguard.com. To participate in the audiocast, please use this link: https://www.bactiguard.com/report/q2-2024/ (https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.bactiguard.com%...